Novel single dose treatment for Influenza - FDA approves Xofluza (Baloxavir marboxil)

Reepa Agrawal
Novel single dose treatment for Influenza - FDA approves Xofluza (Baloxavir marboxil) 02 Nov, 2018

After nearly two decades, a new antiviral drug - Baloxavir marboxil (Xofluza) is now approved by FDA for treatment of influenza. It is a single dose therapy approved for uncomplicated acute influenza in patients 12 years of age and above within 48 hours of onset of symptoms. It is also useful in treatment of patients with oseltamivir resistant influenza.

Baloxavir marboxil is a selective inhibitor of influenza cap- dependent endonuclease. It prevents replication by inhibiting the process known as 'cap snatching' which is performed by cap-dependent endonuclease of PA subunit.

It is administered orally in the dose of 40 mg for patients weighing <80 kg or 80 mg for above 80kgs weight.

This molecule was studied in a phase 3 trial, CAPSTONE -1 and was compared with placebo and oseltamivir (75 mg twice daily for five days), in otherwise healthy people with the flu. It significantly reduced the duration of flu symptoms compared to placebo, and demonstrated similar efficacy compared to oseltamivir

In clinical trials, it was safe and well-tolerated with a side effect profile similar to placebo. Adverse effects seen in about 1% of patients were diarrhea, bronchitis, nasopharyngitis, nausea, sinusitis, headache, vomiting and dizziness.

Baloxavir marboxil is developed by Shinogi Co., a Japanese pharmaceutical company and Roche AG.

It appears to be promising as a single dose for uncomplicated acute influenza but further research is warranted for its use in complicated influenza.
ask a doctor
Ask a Doctor
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0